AR013506A1 - Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida - Google Patents

Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida

Info

Publication number
AR013506A1
AR013506A1 ARP980104682A ARP980104682A AR013506A1 AR 013506 A1 AR013506 A1 AR 013506A1 AR P980104682 A ARP980104682 A AR P980104682A AR P980104682 A ARP980104682 A AR P980104682A AR 013506 A1 AR013506 A1 AR 013506A1
Authority
AR
Argentina
Prior art keywords
salt
budesonide
solvate
manufacture
treatment
Prior art date
Application number
ARP980104682A
Other languages
English (en)
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013506(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR013506A1 publication Critical patent/AR013506A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP980104682A 1997-09-19 1998-09-18 Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida AR013506A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use

Publications (1)

Publication Number Publication Date
AR013506A1 true AR013506A1 (es) 2000-12-27

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104682A AR013506A1 (es) 1997-09-19 1998-09-18 Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida

Country Status (38)

Country Link
US (2) US7897646B2 (enExample)
EP (2) EP1210943B1 (enExample)
JP (1) JP2001517630A (enExample)
KR (1) KR20010024140A (enExample)
CN (1) CN1149998C (enExample)
AR (1) AR013506A1 (enExample)
AT (2) ATE222106T1 (enExample)
AU (1) AU757235B2 (enExample)
BR (1) BR9812325A (enExample)
CA (1) CA2302700C (enExample)
CY (1) CY1106156T1 (enExample)
CZ (1) CZ295250B6 (enExample)
DE (2) DE69807239T2 (enExample)
DK (2) DK1014993T3 (enExample)
EE (1) EE04297B1 (enExample)
ES (2) ES2266322T3 (enExample)
HK (1) HK1045812B (enExample)
HU (1) HUP0003848A2 (enExample)
ID (1) ID24838A (enExample)
IL (1) IL134773A (enExample)
IN (1) IN190791B (enExample)
IS (1) IS2715B (enExample)
MX (1) MXPA00002615A (enExample)
MY (1) MY127812A (enExample)
NO (1) NO327176B1 (enExample)
NZ (1) NZ503173A (enExample)
PL (1) PL190782B1 (enExample)
PT (2) PT1014993E (enExample)
RU (1) RU2199322C2 (enExample)
SA (1) SA98190773B1 (enExample)
SE (1) SE9703407D0 (enExample)
SI (2) SI1210943T1 (enExample)
SK (1) SK285330B6 (enExample)
TR (1) TR200000726T2 (enExample)
TW (1) TW546140B (enExample)
UA (1) UA72446C2 (enExample)
WO (1) WO1999015182A1 (enExample)
ZA (1) ZA988516B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
BR0207062A (pt) * 2001-02-06 2004-10-05 Innovata Biomed Ltd Composição farmacêutica bimodal, inalador para pó seco, método de aplicação de uma quantidade terapeuticamente eficaz de um ingrediente ativo substancialmente fino aos pulmões de um paciente, método de tratamento de um distúrbio respiratório, método de tratamento de doença pulmonar obstrutiva crÈnica (copd), uso de um agente antiinflamatório, uso de um broncodilatador, uso de uma mistura de um agente antiinflamatório e de um broncodilatador, e, processo para a fabricação de uma composição farmacêutica bimodal
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
MX2009004198A (es) * 2006-10-17 2009-10-19 Lithera Inc Metodos, composiciones y formulaciones para el tratamiento de enfermedad ocular tiroidea.
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
GB2477030A (en) * 2010-01-15 2011-07-20 Lithera Inc Lyophilised forms of fluticasone, salmeterol and combinations thereof
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
ES2796177T5 (es) 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651678B1 (fr) 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP0613371B1 (en) 1991-12-18 2002-03-06 AstraZeneca AB New combination of formoterol and budesonide
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
EA002124B1 (ru) * 1995-11-24 2001-12-24 Смитклайн Бичам С.П.А. Производные хинолина
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
EP1009408A1 (en) 1997-06-27 2000-06-21 Astra Aktiebolag New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
TW546140B (en) 2003-08-11
ZA988516B (en) 1999-03-19
RU2199322C2 (ru) 2003-02-27
AU9192898A (en) 1999-04-12
JP2001517630A (ja) 2001-10-09
DE69807239D1 (de) 2002-09-19
SK3892000A3 (en) 2000-12-11
SI1210943T1 (sl) 2006-10-31
CA2302700C (en) 2010-11-23
CA2302700A1 (en) 1999-04-01
US20110097282A1 (en) 2011-04-28
NZ503173A (en) 2001-08-31
US20020042404A1 (en) 2002-04-11
SE9703407D0 (sv) 1997-09-19
PT1014993E (pt) 2002-12-31
CN1271287A (zh) 2000-10-25
EE04297B1 (et) 2004-06-15
DE69834955T2 (de) 2007-01-25
US7897646B2 (en) 2011-03-01
CY1106156T1 (el) 2011-06-08
CZ295250B6 (cs) 2005-06-15
DK1014993T3 (da) 2002-11-11
DE69807239T2 (de) 2003-04-10
ID24838A (id) 2000-08-24
DK1210943T3 (da) 2006-09-18
IL134773A0 (en) 2001-04-30
CN1149998C (zh) 2004-05-19
AU757235B2 (en) 2003-02-06
ES2266322T3 (es) 2007-03-01
SI1014993T1 (en) 2003-02-28
SA98190773B1 (ar) 2006-10-02
NO327176B1 (no) 2009-05-04
TR200000726T2 (tr) 2000-09-21
DE69834955D1 (de) 2006-07-27
ATE329599T1 (de) 2006-07-15
ES2182357T3 (es) 2003-03-01
MY127812A (en) 2006-12-29
KR20010024140A (ko) 2001-03-26
BR9812325A (pt) 2000-09-05
IS2715B (is) 2011-02-15
EP1210943A1 (en) 2002-06-05
HK1045812B (en) 2006-12-22
MXPA00002615A (es) 2002-04-24
IS5407A (is) 2000-03-15
PL190782B1 (pl) 2006-01-31
US20060189587A9 (en) 2006-08-24
EP1014993A1 (en) 2000-07-05
HK1045812A1 (en) 2002-12-13
IL134773A (en) 2005-03-20
IN190791B (enExample) 2003-08-23
EE200000145A (et) 2001-02-15
PL339295A1 (en) 2000-12-04
ATE222106T1 (de) 2002-08-15
CZ2000950A3 (cs) 2000-06-14
NO20001401L (no) 2000-03-17
EP1210943B1 (en) 2006-06-14
SK285330B6 (sk) 2006-11-03
WO1999015182A1 (en) 1999-04-01
NO20001401D0 (no) 2000-03-17
HUP0003848A2 (hu) 2001-08-28
UA72446C2 (uk) 2005-03-15
PT1210943E (pt) 2006-09-29
EP1014993B1 (en) 2002-08-14
US8461211B2 (en) 2013-06-11

Similar Documents

Publication Publication Date Title
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
WO2005046640A3 (en) Multi-site drug delivery platform
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
ATE398999T1 (de) Aerosol-formulierungen von formoterol und mometason
AR033688A1 (es) Composicion parenteral reconstituible
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
JP2002528502A5 (enExample)
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure